TissGeneSummary for GLIPR1L2 |
Gene summary |
Basic gene information | Gene symbol | GLIPR1L2 |
Gene name | GLI pathogenesis-related 1 like 2 | |
Synonyms | - | |
Cytomap | UCSC genome browser: 12q21.2 | |
Type of gene | protein-coding | |
RefGenes | NM_001270396.1, NM_152436.2,NR_072995.1, | |
Description | GLIPR1-like protein 2 | |
Modification date | 20141207 | |
dbXrefs | MIM : 610394 | |
HGNC : HGNC | ||
Ensembl : ENSG00000180481 | ||
HPRD : 17538 | ||
Vega : OTTHUMG00000169756 | ||
Protein | UniProt: go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_GLIPR1L2 | |
BioGPS: 144321 | ||
Pathway | NCI Pathway Interaction Database: GLIPR1L2 | |
KEGG: GLIPR1L2 | ||
REACTOME: GLIPR1L2 | ||
Pathway Commons: GLIPR1L2 | ||
Context | iHOP: GLIPR1L2 | |
ligand binding site mutation search in PubMed: GLIPR1L2 | ||
UCL Cancer Institute: GLIPR1L2 | ||
Assigned class in TissGDB* | B | |
Included tissue-specific gene expression resources | HPA,TiGER,GTEx | |
Specific-tissues in normal samples (assigned by TissGDB using HPA, TiGER, and GTEx) | Testis | |
Cancer types related to the specific-tissues in cancer samples (assigned by TissGDB using TCGA) | TGCT | |
Reference showing the relevant tissue of GLIPR1L2 | ||
Description by TissGene annotations |
* Class A consists of genes with literature evidence and is part of the cTissGenes. Class B consists of only cTissGenes without additional evidence. The remaining genes belong to Class C. |
Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
GO ID | GO term | PubMed ID |
Top |
TissGeneExp for GLIPR1L2 |
Gene expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
Gene isoform expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA pan-cancer tcga_rsem_isoform_tpm, version 2016-09-01) |
Gene expressions across normal tissues of GTEx data (GTEx GTEx_Analysis_v6_RNA-seq_RNA-SeQCv1.1.8_gene_rpkm.gct) - Here, we shows the matched tissue types only among our 28 cancer types. |
Different expressions across 14 cancer types with more than 10 samples between matched tumors and normals (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
- Significantly differentially expressed cancer types and information. (|Fold change|>1 and FDR<0.05) |
Cancer type | Mean(exp) in tumor | Mean(exp) in matched normal | Log2FC | P-val. | FDR |
LUSC | -0.849348047 | 0.277473522 | -1.126821569 | 3.27E-07 | 8.68E-07 |
KIRP | -0.599404236 | 1.190064514 | -1.78946875 | 1.05E-06 | 5.36E-06 |
THCA | 0.621976114 | 1.749816792 | -1.127840678 | 9.10E-08 | 3.97E-07 |
LUAD | -0.753680636 | 0.437202122 | -1.190882759 | 3.83E-09 | 1.84E-08 |
HNSC | -1.609188174 | -0.227497477 | -1.381690698 | 9.42E-10 | 1.54E-08 |
KICH | -0.563032361 | 1.534007639 | -2.09704 | 3.71E-07 | 1.51E-06 |
BLCA | -1.506553413 | 0.123725534 | -1.630278947 | 0.000273 | 0.002508893 |
STAD | -1.396419861 | -0.214872986 | -1.181546875 | 3.56E-05 | 0.000325465 |
Top |
TissGene-miRNA for GLIPR1L2 |
Significantly anti-correlated miRNAs of TissGene across 28 cancer types (Gene-miRNA relations from TargetScanHuman Relsease 7.1, Conserved_Site_Context_Scores.txt.zip, 06.01.2016) (TCGA IlluminaHiSeq_miRNASeq, log2(RPM+1) data, version 2016-11-21) (TCGA IlluminaHiSeq_RNASeqV2, log2(normalized_count+1) data, version 2016-08-16) (Spearman’s Rank Correlation (p-value<0.05 and coefficient<-0.25)) |
Cancer type | miRNA id | miRNA accession | P-val. | Coeff. | # samples |
Top |
TissGeneMut for GLIPR1L2 |
TissGeneSNV for GLIPR1L2 |
nsSNV counts per each loci. Different colors of circles represent different cancer types. Circle size denotes number of samples. (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) * Click on the image to enlarge it in a new window. |
Somatic nucleotide variants of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of mutated samples) The numbers in parentheses are numbers of samples with mutation (nsSNVs). (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) |
- nsSNVs sorted by frequency. |
AAchange | Cancer type | # samples |
p.A193V | STAD | 2 |
p.A193V | ESCA | 1 |
p.E204K | BLCA | 1 |
p.R245W | SARC | 1 |
p.L222I | UCEC | 1 |
p.C151F | LUAD | 1 |
p.S136R | STAD | 1 |
p.R135I | LUAD | 1 |
p.K228T | READ | 1 |
p.G123C | ESCA | 1 |
p.F249L | SKCM | 1 |
p.P46S | STAD | 1 |
p.G123S | LUSC | 1 |
p.W241L | ESCA | 1 |
p.E48K | LUSC | 1 |
p.W163L | SKCM | 1 |
p.A19E | STAD | 1 |
p.R89I | ACC | 1 |
p.I116M | LUAD | 1 |
p.R244Q | SKCM | 1 |
p.P111S | SKCM | 1 |
p.A193V | LIHC | 1 |
p.R201S | OV | 1 |
p.A193V | COAD | 1 |
p.T210A | STAD | 1 |
p.R211Q | OV | 1 |
p.V82I | BLCA | 1 |
p.K112E | HNSC | 1 |
p.K240N | COAD | 1 |
p.G123D | SKCM | 1 |
p.E127K | SKCM | 1 |
p.D154Y | BLCA | 1 |
p.T199M | STAD | 1 |
p.Y167H | LUSC | 1 |
p.V169A | SKCM | 1 |
p.D67N | HNSC | 1 |
p.P70T | KIRP | 1 |
p.M1T | BLCA | 1 |
p.W163R | BLCA | 1 |
p.G117V | LUSC | 1 |
p.E140D | BLCA | 1 |
p.T199R | LUAD | 1 |
p.R211Q | BRCA | 1 |
p.T163I | UCEC | 1 |
Top |
TissGeneCNV for GLIPR1L2 |
Copy number variations of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of CNV samples) (TCGA Gistic2_CopyNumber_Gistic2_all_data_by_genes, Gistic2 copy number data, version 2016-08-16) |
Top |
TissGeneFusions for GLIPR1L2 |
Fusion genes including TissGene (ChimerDB 3.0, 2016-12-01 and TCGA fusion Portal 2015-12-01) |
Database | Src | Cancer type | Sample | Fusion gene | ORF | 5'-gene BP | 3'-gene BP |
Top |
TissGeneNet for GLIPR1L2 |
Co-expressed gene networks based on protein-protein interaction data (CePIN) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (PINA2 ppi data) |
Top |
TissGeneProg for GLIPR1L2 |
Kaplan-Meier plots with logrank tests of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image to enlarge it in a new window. |
Kaplan-Meier plots with logrank test of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Forest plot of Cox proportional hazard ratio (HR) and 95% CI of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Forest plot of Cox proportional hazard ratio (HR) and 95% CI of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Top |
TissGeneClin for GLIPR1L2 |
TissGeneDrug for GLIPR1L2 |
Drug information targeting TissGene (DrugBank Version 5.0.6, 2017-04-01) |
DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
TissGeneDisease for GLIPR1L2 |
Disease information associated with TissGene (DisGeNet, 2016-06-01) |
Disease ID | Disease name | # pubmeds | Source |